The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
暂无分享,去创建一个
Mary Frances McMullin | Stefan N Constantinescu | Melanie J Percy | Joanne Elliott | William Vainchenker | J. Johnston | S. Constantinescu | W. Vainchenker | J. Staerk | M. McMullin | A. Ward | M. Percy | Joanne Elliott | Yvonne Suessmuth | James A Johnston | Michelle B Hookham | Yvonne Suessmuth | Judith Staerk | Alister C Ward | Michelle B. Hookham
[1] K. Liedl,et al. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. , 2001, Protein engineering.
[2] J. Johnston,et al. The Chemoattractants, IL-8 and Formyl-Methionyl-Leucyl-Phenylalanine, Regulate Granulocyte Colony-Stimulating Factor Signaling by Inducing Suppressor of Cytokine Signaling-1 Expression1 , 2004, The Journal of Immunology.
[3] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[4] D. Hilton,et al. Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1 , 2002, Molecular and Cellular Biology.
[5] J. G. Zhang,et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. Erkeland,et al. Suppressor of cytokine signaling 3 controls lysosomal routing of G‐CSF receptor , 2007, The EMBO journal.
[7] N. Danial,et al. v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells. , 2004, Molecular cell.
[8] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[9] H. Lodish,et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[10] P. Heinrich,et al. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. , 2002, European journal of biochemistry.
[11] J. Johnston,et al. SOCS2 Can Enhance Interleukin-2 (IL-2) and IL-3 Signaling by Accelerating SOCS3 Degradation , 2005, Molecular and Cellular Biology.
[12] Keiichi I Nakayama,et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. , 2004, Genes & development.
[13] J. Johnston,et al. Tyrosine Phosphorylation Disrupts Elongin Interaction and Accelerates SOCS3 Degradation* , 2003, Journal of Biological Chemistry.
[14] J. Johnston,et al. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras , 2001, Nature Cell Biology.
[15] J. Johnston,et al. SOCS-3 Is Tyrosine Phosphorylated in Response to Interleukin-2 and Suppresses STAT5 Phosphorylation and Lymphocyte Proliferation , 1999, Molecular and Cellular Biology.
[16] John Calvin Reed,et al. Granzyme Release and Caspase Activation in Activated Human T-Lymphocytes* , 1998, The Journal of Biological Chemistry.
[17] J. Kutok,et al. Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.
[18] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[19] W. Alexander,et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL‐6 signal transduction , 1999, The EMBO journal.
[20] S. Constantinescu,et al. JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation , 2005, Journal of Biological Chemistry.
[21] Qingshan Li,et al. Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.
[22] M. Nawijn,et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.